Postmenopausal hormone therapy and risk of cardiovascular disease and hip fracture in a cohort of Swedish women

Epidemiology

Volumn 10, Issue 5, 1999, Pages 476-480

  Grodstein, Francine ^a,b,e   Stampfer, Meir J ^a,b   Falkeborn, Margareta ^c   Naessen, Tord ^c   Persson, Ingemar ^d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UPPSALA UNIVERSITY   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

^e CHANNING LABORATORY   (United States)

Author keywords

Cardiovascular disease; Hip fracture; Hormones; Menopause

Indexed keywords

ESTROGEN DERIVATIVE; PROGESTERONE DERIVATIVE;

ADULT; ARTICLE; CARDIOVASCULAR RISK; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; ESTROGEN THERAPY; FEMALE; HEALTH BEHAVIOR; HEART INFARCTION; HIP FRACTURE; HUMAN; INCIDENCE; LONG TERM CARE; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; STROKE; SWEDEN; TREATMENT OUTCOME;

EID: 0032772329     PISSN: 10443983     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001648-199909000-00003     Document Type: Article

References (30)

1. Grodstein F, Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis 1995; 38:199-210.
2. Barrett-Connor E. Postmenopausal estrogen and prevention bias. Ann Intern Med 1991;115:455-456.
3. Matthews KA, Kuller LH, Wing RR, Meilahn EN, Plantinga P. Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol 1996;143:971-978.
4. Falkeborn M, Persson I, Adami HO, Bergstrom R, Eaker E, Mohsen HLR, Naessen T. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol 1992;99:821-828.
5. Falkeborn M, Persson I, Terent A, Adami HO, Lithell H, Bergstrom R. Hormone replacement therapy and the risk of stroke. Follow-up of a population-based cohort in Sweden. Arch Intern Med 1993;153:1201-1209.
6. Naessen T, Persson I, Adami HO, Bergstrom R, Bergkvist L. Hormone replacement therapy and the risk for first hip fracture. A prospective, population-based cohort study. Ann Intern Med 1990;113:95-103.
7. Persson I, Adami HO, Johansson E, Lindberg B, Manell P, Westerholm B. Cohort study of oestrogen treatment and the risk of endometrial cancer: evaluation of method and its applicability. Eur J Clin Pharmacol 1983;25: 625-632.
8. Harmsen P, Tsipogianni A, Wilhelmsson L. Stroke incidence rates were unchanged while fatality rates declined during 1971-1987 in Goteborg, Sweden. Stroke 1992;23:1410-1415.
9. Jerntorp P, Berglund G. Stroke registry in Malmo, Sweden. Stroke 1992;23: 357-361.
10. Hammar N , Nerbrand C, Ahlmark G, Tibblin G, Tsipogianni A, Johansson S, Wilhelmsen L, Jacobsson S, Hansen O. Identification of cases of myocardial infarction: hospital discharge data and mortality data compared to myocardial infarction community registers. Int J Epidemiol 1991;20:114-120.
11. Naessen T, Parker R, Persson I, Zack M, Adami HO. Time trends in incidence rates of first hip fractures 1965-83: A registry-based study in Sweden. Am J Epidemiol 1989;130:289-299.
12. Falkeborn M, Persson I, Terent A, Bergstrom R, Lithell H, Naessen T. Long-term trends in incidence of and mortality from acute myocardial infarction and stroke in women: analyses of total first events and of deaths in the Uppsala Health Care Region, Sweden. Epidemiology 1996;7:67-74.
13. Rothman KJ, Boice JD. Epidemiologic analysis with a programmable calculator (NIH Pub. No. 79-1649). Washington DC: Public Health Service, 1979.
14. Cox DR. Regression models and life-tables. J R Stat Soc B 1972;34:187-220.
15. Cauley JA, Cummings SR, Black DM, Mascioli SR, Seeley DG. Prevalence and determinants of estrogen replacement therapy in elderly women. Am J Obstet Gynecol 1990;163:1438-1444.
16. Grodstein F. Invited commentary: can selection bias explain the cardiovascular benefits of estrogen replacement therapy? Am J Epidemiol 1996;143: 979-982.
17. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453-461.
18. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991;151:75-78.
19. Paganini-Hill A, Chao A, Ross RK, Henderson BE. Exercise and other factors in the prevention of hip fracture: the Leisure World Study. Epidemiology 1991;2:16-25.
20. Coronary Drug Project Research Group. Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N Engl J Med 1980;303:1038-1041.
21. Postmenopausal Estrogen/Progestin Interventions Trial Writing Group. Effects of estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995;273:199-208.
22. Wagner JD, Clarkson TB, St Clair RW, Schwenke DC, Shively CA, Adams MR. Estrogen and progesterone replacement therapy reduces low density lipoprotein accumulation in the coronary arteries of surgically postmenopausal cynomolgus monkeys. J Clin Invest 1991;88:1995-2002.
23. Adams MR, Kaplan JR, Manuck SB, Koritnik DR, Parks JS, Wolfe MS, Clarkson TB. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis 1990;10:1051-1057.
24. Collins P, Rosano GM, Sarrel PM, Ulrich L, Adamopoulos S, Beale CM, McNeill JG, Poole-Wilson PA. 17 beta-estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation 1995;92:24-30.
25. Gangar KF, Vyas S, Whitehead M, Crook D, Meire H, Campbell S. Pulsatility index in internal carotid artery in relation to transdermal oestradiol and time since menopause. Lancet 1991;338:839-842.
26. Christiansen C, Christensen MS, Transbol I. Bone mass in postmenopausal women after withdrawal of estrogen/gestogen replacement therapy. Lancet 1981;1:459-461.
27. Naessen T, Lindmark B, Larsen HC. Better postural balance in elderly women receiving estrogens. Am J Obstet Gynecol 1997;177:412-416.
28. Sullivan JM, Shala BA, Miller LA, Lerner JL, McBrayer JD. Progestin enhances vasoconstrictor responses in postmenopausal women receiving estrogen replacement therapy. Menopause 1995;2:193-199.
29. Gangar KF, McCullogh W, Penny J, Gangar E, Morris J. Continuous combined hormone replacement therapy and cardiovascular protection. Eur Menopause J 1996;3:147-150.
30. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-613.